Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.

Martín-Jiménez, M; Rodríguez-Lescure, A; Ruiz-Borrego, M; Seguí-Palmer, M-A; Brosa-Riestra, M

Martín-Jiménez, M; Rodríguez-Lescure, A; Ruiz-Borrego, M; Seguí-Palmer, M-A; Brosa-Riestra, M.

Affiliation

Martín-Jiménez M; Hospital Universitario San Carlos, Madrid, Spain.

Clin Transl Oncol ; 11(1): 41-7, 2009 Jan.

Article in En | MEDLINE | ID: mdl-19155203

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/economics; Breast Neoplasms/drug therapy; Breast Neoplasms/economics; Fluorouracil/economics; Taxoids/economics; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/mortality; Cost-Benefit Analysis; Cyclophosphamide/administration & dosage; Cyclophosphamide/adverse effects; Docetaxel; Doxorubicin/administration & dosage; Doxorubicin/adverse effects; Female; Fluorouracil/adverse effects; Fluorouracil/therapeutic use; Humans; Models, Economic; Quality-Adjusted Life Years; Taxoids/administration & dosage; Taxoids/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Taxoids / Fluorouracil Type of study: Clinical_trials / Health_economic_evaluation Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Clin Transl Oncol Year: 2009 Document type: Article Affiliation country: Spain Country of publication: Italy

Search on Google

Add to My VHL

XML

PubMed Links